Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus HUMATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GENTAFAIR versus HUMATIN.
GENTAFAIR vs HUMATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
15-25 mg/kg/day orally in 4 divided doses for hepatic coma; 50 mg/kg/day orally in 4 divided doses for infectious diarrhea, max 4 g/day.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
2-3 hours (serum half-life of absorbed fraction); clinically negligible due to minimal systemic absorption
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Primarily unchanged in feces (~90%); small amount absorbed is excreted renally as unchanged drug (~1%)
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic